In the phase I clinical trial reported here, we evaluate the DNAJB1-PRKACA fusion transcript-based neoepitope vaccine Fusion-VAC-XS15 in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody atezolizumab (TecentriqTM) in patients with FL-HCC or other locally advanced or metastatic cancer entities carrying the DNAJB1-PRKACA fusion transcript. Here, CD274 is linked to metastatic malignant neoplasm.